All In Biotech

Investigational drug · Phase 2

KAN-101

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease, Coeliac Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

3

Any phase or sponsor naming "KAN-101"

First trial start

2023

Dec 13, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "KAN-101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Celiac Disease
  • Coeliac Disease

Approved drugs for the same conditions: Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "KAN-101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Celiac Disease

  • AmlitelimabSAR445229Phase 39 trials

    Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease

  • TEV-53408Phase 32 trials

    Teva · Vitiligo, Celiac Disease

  • Larazotide AcetatePhase 31 trial

    Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents

  • DONQ52Phase 21 trial

    Chugai Pharmaceutical · Celiac Disease

  • FB102Phase 21 trial

    Forte Biosciences, Inc. · Celiac Disease

  • TAK-101Phase 21 trial

    Takeda · Celiac Disease

  • ZED1227Phase 21 trial

    Dr. Falk Pharma GmbH · Celiac Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.